Eli Lilly and Co to Discuss Diabetes Portfolio Update at ADA Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : Going to start with the obvious. Mike, how are you thinking about the impact of tirzepatide on the GLP-1 market, including Trulicity? And then secondly, what have you observed, so far, since the oral GLP-1 launch in terms of the commercial experience and how and when and where it's being used? And how does that shape your thinking about where an oral product fits in, in the future for Lilly?

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Two questions for me, please. Firstly, on tirzepatide. You discussed here that having the potential best-in-class drug, even at the lowest 5-mg dose. So I wonder if you can talk more about what proportion of patients in the clinic, in real life you think will be adequately treated with the low dose, those that might require titration up to the highest dose. And then on the weekly insulin, you are behind Novo here to report Phase III data to [lay] into an [IPD] next year. What can you do to close that gap? Is that a key focus for you? Or actually, do you see a differentiating element to this? I mean do you worry less about coming second to market with weekly insulin?